ATE472598T1 - Cd4+cd25+ regulatorische t-zellen aus menschlichem blut - Google Patents

Cd4+cd25+ regulatorische t-zellen aus menschlichem blut

Info

Publication number
ATE472598T1
ATE472598T1 AT02727397T AT02727397T ATE472598T1 AT E472598 T1 ATE472598 T1 AT E472598T1 AT 02727397 T AT02727397 T AT 02727397T AT 02727397 T AT02727397 T AT 02727397T AT E472598 T1 ATE472598 T1 AT E472598T1
Authority
AT
Austria
Prior art keywords
cells
regulatory
human blood
suppressive
human
Prior art date
Application number
AT02727397T
Other languages
English (en)
Inventor
Gerold Schuler
Detlef Dieckmann
Original Assignee
Argos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE472598(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Argos Therapeutics Inc filed Critical Argos Therapeutics Inc
Application granted granted Critical
Publication of ATE472598T1 publication Critical patent/ATE472598T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002—Partitioning blood components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02727397T 2001-03-12 2002-03-12 Cd4+cd25+ regulatorische t-zellen aus menschlichem blut ATE472598T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01106033A EP1241249A1 (de) 2001-03-12 2001-03-12 Regulatorische CD4+CD25+ T Zellen aus menschlichem Blut
PCT/EP2002/002671 WO2002072799A1 (en) 2001-03-12 2002-03-12 Cd4+cd25+ regulatory t cells from human blood

Publications (1)

Publication Number Publication Date
ATE472598T1 true ATE472598T1 (de) 2010-07-15

Family

ID=8176748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02727397T ATE472598T1 (de) 2001-03-12 2002-03-12 Cd4+cd25+ regulatorische t-zellen aus menschlichem blut

Country Status (10)

Country Link
EP (2) EP1241249A1 (de)
JP (3) JP2004529631A (de)
KR (3) KR20030088037A (de)
CN (2) CN1509327B (de)
AT (1) ATE472598T1 (de)
AU (2) AU2002257648B2 (de)
BR (1) BR0208076A (de)
CA (1) CA2441213C (de)
DE (1) DE60236858D1 (de)
WO (1) WO2002072799A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
WO1999048524A1 (en) 1998-03-03 1999-09-30 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
EP1241249A1 (de) * 2001-03-12 2002-09-18 Gerold Schuler Regulatorische CD4+CD25+ T Zellen aus menschlichem Blut
AU2002364230B2 (en) * 2001-12-21 2008-05-01 University Of Southern California Methods for the induction of professional and cytokine-producing regulatory cells
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
US7479123B2 (en) 2002-03-04 2009-01-20 Therakos, Inc. Method for collecting a desired blood component and performing a photopheresis treatment
US7211037B2 (en) 2002-03-04 2007-05-01 Therakos, Inc. Apparatus for the continuous separation of biological fluids into components and method of using same
ES2422193T3 (es) * 2002-06-28 2013-09-09 Life Technologies Corp Métodos para restaurar el repertorio inmune en pacientes con defectos inmunológicos relacionados con la autoinmunidad y trasplante de órganos o de células madre hematopoyéticas
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
EP1391210A3 (de) * 2002-08-12 2007-10-31 Gerold Schuler Regulatorisches Medikament enthaltend CD4+CD25- T Zellen und Tr1-analoge regulatorische Zellen
GB0302167D0 (en) * 2003-01-30 2003-03-05 Leuven K U Res & Dev T cell phenotype
EP1460088A1 (de) * 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
CA2537900A1 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
FR2864546A1 (fr) * 2003-12-24 2005-07-01 Assist Publ Hopitaux De Paris Methode d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations
WO2005118788A2 (en) * 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
JP2007320852A (ja) * 2004-10-22 2007-12-13 Kyoto Univ 肝障害の予防又は治療方法
US7476209B2 (en) 2004-12-21 2009-01-13 Therakos, Inc. Method and apparatus for collecting a blood component and performing a photopheresis treatment
DE102005002110A1 (de) * 2005-01-17 2006-07-27 Protagen Ag Regulatorische-T-Zellen enthaltend Proteine zur Therapie und Diagnose von Erkrankungen
EP1851308B1 (de) * 2005-02-02 2013-08-21 NewSouth Innovations Pty Limited Gegen ein spezifisches antigen aktivierte cd4+ cd25+ t-zellen
WO2006111986A1 (en) * 2005-04-19 2006-10-26 Fondazione Santa Lucia I.R.C.C.S. Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof
WO2006133398A2 (en) * 2005-06-08 2006-12-14 Invitrogen Corporation In vitro activated donor t-cells to promote transplant engraftment
US8916147B2 (en) 2005-08-24 2014-12-23 Yeda Research and Devolpment Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
KR101536239B1 (ko) * 2005-09-23 2015-07-13 셀레릭스, 에스.엘. 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도
PL1989544T3 (pl) * 2006-03-02 2012-01-31 Antitope Ltd Testy na komórkach T
GB0604170D0 (en) * 2006-03-02 2006-04-12 Antitope Ltd T cell assays
FR2898275B1 (fr) * 2006-03-10 2012-12-14 Genethon Cellules t regulatrices cd4+cd25+specifiques pour la greffe de cellules hematopoietiques et la tolerance immunitaire
WO2008014555A1 (en) 2006-08-02 2008-02-07 Newsouth Innovations Pty Limited Method of identifying cd4+cd25+ t cells activated to an antigen which express cd8
WO2008092905A2 (en) 2007-02-01 2008-08-07 Boehringer Ingelheim International Gmbh Specific activation of a regulatory t cell and its use for treatment of asthma, allergic disease, autoimmune disease, graft rejection and for tolerance induction
EP2265643B1 (de) 2008-03-13 2016-10-19 Biotest AG Dosierungsschema zur behandlung von psoriasis und rheumatoider arthritis
RU2540013C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
EP2260057B1 (de) 2008-03-13 2016-11-23 Biotest AG Anti-CD4 Antikörper Dosierungsschema zur Behandlung von Autoimmunkrankheiten
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2012011113A2 (en) 2010-07-22 2012-01-26 Shai Yarkoni Regulatory immune cells with enhanced targeted cell death effect
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2603520A4 (de) * 2010-08-10 2014-02-19 Ecole Polytech Erythrozytenbindende therapeutika
WO2013035099A1 (en) * 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
CA2782942C (en) 2012-07-12 2019-08-27 Canadian Blood Services Method for inducing immune tolerance using polymer-modified antigenic leukocytes
DK3019176T3 (da) 2013-07-12 2020-06-22 Canadian Blood Services Anvendelse af acellulære pro-inflammatoriske sammensætninger og fremgangsmåde til fremstilling heraf
CN103464691A (zh) * 2013-09-26 2013-12-25 北京北方车辆集团有限公司 主动轮齿盘毛坯的铸造方法
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG11201606761RA (en) 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
WO2016004538A1 (en) 2014-07-10 2016-01-14 Canadian Blood Services Combination therapy of a cellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system
CN106566806B (zh) * 2016-07-11 2018-05-04 英威福赛生物技术有限公司 体外培养富集cd8+t细胞的方法
KR101885221B1 (ko) * 2016-10-25 2018-08-06 (주)에이온엘에스 말초혈액단핵구 유래 조절 t 세포 배양용 배지 조성물 및 이를 이용한 조절 t 세포 배양방법
WO2018106885A1 (en) 2016-12-07 2018-06-14 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
CN108084263B (zh) * 2016-12-16 2021-07-13 苏州旭光科星抗体生物科技有限公司 一种抗人cd25嵌合单克隆抗体及其制备方法和应用
CN107083360B (zh) * 2017-05-23 2019-07-05 华中科技大学同济医学院附属同济医院 一种体外诱导扩增人抗原非特异性调节性t细胞的方法
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CN109957544B (zh) * 2017-12-22 2023-09-12 财团法人工业技术研究院 体外活化及/或扩增免疫细胞的方法
CN108588021A (zh) * 2018-05-02 2018-09-28 深圳市因诺转化医学研究院 分离和纯化til、获取cd4＋cd25+细胞亚群的方法
EP3790577A4 (de) 2018-05-09 2022-04-27 The University of Chicago Zusammensetzungen und verfahren im zusammenhang mit immuntoleranz
CN108588022B (zh) * 2018-05-10 2019-12-10 英威福赛生物技术有限公司 体外培养富集人cd4+和cd8+ tcm细胞的方法
US20230338421A1 (en) * 2020-01-10 2023-10-26 TCR2 Therapeutics Inc. Compositions and methods for autoimmunity regulation
CN114480279A (zh) * 2022-01-18 2022-05-13 吉林省真承药业有限公司 一种高效的人类血液免疫细胞cd4t分离培养技术

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2196002T3 (es) * 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
AU748533B2 (en) * 1997-06-11 2002-06-06 United States Of America As Represented By The Secretary Of The Navy, The Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses
AU767756C (en) * 1999-01-22 2004-08-12 Schepens Eye Research Institute, Inc., The Activation of regulatory T cells by alpha-melanocyte stimulating hormone
DE60042210D1 (de) * 1999-09-01 2009-06-25 Univ Southern California Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
EP1241249A1 (de) * 2001-03-12 2002-09-18 Gerold Schuler Regulatorische CD4+CD25+ T Zellen aus menschlichem Blut

Also Published As

Publication number Publication date
JP2009060894A (ja) 2009-03-26
CN1509327A (zh) 2004-06-30
BR0208076A (pt) 2004-03-02
JP2011041570A (ja) 2011-03-03
AU2008201685A1 (en) 2008-05-08
DE60236858D1 (de) 2010-08-12
EP1379625B1 (de) 2010-06-30
CA2441213C (en) 2014-01-07
EP1379625A1 (de) 2004-01-14
KR20030088037A (ko) 2003-11-15
CN1509327B (zh) 2010-10-20
JP2004529631A (ja) 2004-09-30
AU2008201685B2 (en) 2011-03-31
CN101385742A (zh) 2009-03-18
JP4714767B2 (ja) 2011-06-29
EP1241249A1 (de) 2002-09-18
KR20110047279A (ko) 2011-05-06
KR20090126329A (ko) 2009-12-08
KR101301923B1 (ko) 2013-08-30
WO2002072799A1 (en) 2002-09-19
CA2441213A1 (en) 2002-09-19
AU2002257648B2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
ATE472598T1 (de) Cd4+cd25+ regulatorische t-zellen aus menschlichem blut
IL249263B (en) Method for ex-vivo organ care
NL1026892A1 (nl) ó1,8!Naftyridin-2-onen en verwante verbindingen voor de behandeling van schizofrenie.
DE60309934D1 (de) Heim- und körperpflegezusammensetzungen,die gleitmittel auf silikongrundlage enthalten
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
WO2003009773A8 (en) Removable stent and method of using the same
BR0215405A (pt) Composições e processos de uso de collajolie
BR0112969A (pt) Método de utilização de dicetopiperazinas e composições contendo-as
ECSP045245A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados
DE602004019917D1 (de) Bandscheibenimplantate und methoden zu deren herstellung
PT1453512E (pt) Derivados de acetileno tendo actividade antagonistica do mglur 5
NO20091976L (no) Nye forbindelser
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
WO2005013805A3 (en) Systemand methods for performing dynamic pedicle integrity assessments
HN2000000109A (es) Trifluorbutenos nematicidas
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
ITMI20022758A1 (it) Nuovi uracili ad attivita' erbicida.
NO20044898L (no) Nye etonogestrel estere
ITMI20031847A1 (it) Composizione di fluoropolimeri espandibili senza l'impiego di agenti espandenti.
ATE383384T1 (de) Selbstemulgierende wässrige polyurethandispersionen
MXPA04003755A (es) Endoprotesis vasculares.
DK1532131T3 (da) Motilid-forbindelser
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos
PL372940A1 (en) Ciclesonide-containing sterile aqueous suspension
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties